MedGenome, a leading global genomics-driven diagnostics and research services company, announced the appointment of Dr. Amit ...

and BANGALORE, India, Sept ... a global life sciences investor wholly owned by the Novo Nordisk Foundation, an independent philanthropic enterprise foundation. He has over 30 years of experience ...

No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide has been shown to induce ...

Foster City (California) [US]/ Bangalore (Karnataka) [India], September 11 ... a global life sciences investor wholly owned by the Novo Nordisk Foundation, an independent philanthropic enterprise ...

Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...